English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective: To carry out an integrative review of the literature on biological therapy in Crohn's disease, bringing a positive focus on the therapeutic results observed with the drugs infliximab and adalimumab. Method: The present study is an integrative review of the literature, carried out between June and December 2018, with the guiding question: "How does biological therapy in Crohn's disease promote positive therapeutic results with the use of drugs infliximab and adalimumab?" The bibliographic survey was done using the Internet digital resource, in the SciELO (Scientific Electronic Library Online) and LILACS (Latin American and Caribbean Literature in Health Sciences) databases. For the search of the scientific articles, crossing mechanisms were used with the following descriptors: "Crohn's disease", "Infliximab", "Adalimumab" and "Biological Therapy". Among the inclusion criteria were: articles published in Portuguese, English and Spanish; to make their contents available in a free way; published and indexed from 2009 to 2018; and to attend to what was proposed the research object of this study, excluding documentary work formats of course completion, dissertation and thesis. Results: Crohn's disease encompasses the group of inflammatory bowel diseases. Because it does not have pathogenesis still well understood, its treatment is considered a challenging question. Biological therapy, through the drugs infliximab and adalimumab, has promoted positive therapeutic results for this pathological condition. Improvements were observed, such as the reduction of exacerbation outbreaks and their frequencies, disease control, induction of remission and reduction of hospitalizations, often associated with organic processes such as induction of T lymphocyte apoptosis, recovery of the integrity of the epithelial barrier and induction of mobility of fibroblasts present in the intestine, culminating in the healing of lesions. Conclusion: Crohn's disease, besides promoting potentially negative changes in the quality of life of its patients, still constitutes a challenge for the precise establishment of its pathophysiological, diagnostic and therapeutic bases. In this perspective, investigating drugs used in their treatment, such as infliximab and adalimumab, is of

TERAPIA BIOLÓGICA NA DOENÇA DE CROHN: UM ENFOQUE POSITIVO NOS RESULTADOS TERAPÊUTICOS OBSERVADOS COM OS FÁRMACOS INFLIXIMABE E ADALIMUMABE